Related Experiment Video
Updated: May 21, 2026

Isolation of Human Atrial Myocytes for Simultaneous Measurements of Ca2+ Transients and Membrane Currents
Published on: July 3, 2013
Pharmacology of myocardial calcium-handling
1Division of Rhythmology, Department of Cardiology and Angiology, University Hospital Muenster, Albert-Schweitzer-Campus 1, 48149 Muenster, Germany. julia.vogler@ukmuenster.de
Insights
Impaired myocardial calcium handling is key in heart diseases. Treatments aim to restore calcium homeostasis using current and novel pharmacologic agents targeting calcium-dependent pathways.
Area of Science:
- Cardiovascular Pharmacology
- Molecular Cardiology
- Biomedical Science
Background:
- Disturbed myocardial calcium (Ca2+) handling is a hallmark of cardiovascular diseases like heart failure and hypertrophy.
- Abnormal Ca2+ handling also contributes to tachyarrhythmias.
- Restoring myocardial Ca2+ homeostasis is a primary therapeutic goal.
Purpose of the Study:
- To review current pharmacologic agents for restoring myocardial Ca2+ homeostasis.
- To discuss the mechanisms of action of these agents.
- To highlight emerging substances for cardiovascular disease treatment.
Main Methods:
- Literature review of pharmacologic agents.
- Analysis of mechanisms targeting Ca2+-dependent signaling pathways.
- Synthesis of information on established and novel treatments.
Main Results:
- Identified key pharmacologic strategies targeting myocardial Ca2+ homeostasis.
- Detailed mechanisms of action for existing drugs.
- Summarized potential of new therapeutic substances.
Conclusions:
- Pharmacologic interventions targeting myocardial Ca2+ homeostasis are crucial for cardiovascular diseases.
- Understanding Ca2+ handling mechanisms informs drug development.
- Novel agents show promise for improved treatment of heart conditions.
Abstract:
Disturbed myocardial calcium (Ca(+)) handling is one of the pathophysiologic hallmarks of cardiovascular diseases such as congestive heart failure, cardiac hypertrophy, and certain types of tachyarrhythmias. Pharmacologic treatment of these diseases thus focuses on restoring myocardial Ca(2+) homeostasis by interacting with Ca(2+)-dependent signaling pathways. In this article, we review the currently used pharmacologic agents that are able to restore or maintain myocardial Ca(2+) homeostasis and their mechanism of action as well as emerging new substances.
Related Concept Videos
Antihypertensive Drugs: Action of Calcium Channel Blockers
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Pathophysiology of Cardiac Performance
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Coronary Artery Disease V: Interprofessional Care

